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Correction
Following publication of their article [1], the authors 
noticed that Table 2 should list medium chain tri gly-
cerides (MCT) instead of olive oil emulsion (OO) in the 
column ‘Standard lipid emulsion’ as follows;
- For the study Barbosa 2010 [7], this column should 
read SO/MCT
- For the study Berger 2008 [8], this column should 
read SO/MCT
- For the study Friesecke 2008 [9], this column should 
read SO/MCT 
- For the study Wachtler 1997 [15], this column should 
read SO/MCT
- For the study Klek 2005 [22], this column should read 
SO/MCT
- For the study Senkal 2007 [28], this column should 
read SO/MCT
Th e correct version of the table appears overleaf.
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Table 2. Studies evaluating n-3 PUFA-enriched lipid emulsions for parenteral nutrition and reported outcomes/measured 
parameters
  n-3 PUFA- Standard 
  enriched lipid lipid 
Study Setting (n) emulsion emulsion Clinical outcomes Laboratory outcomes
ICU patientsa (n = 762)
Antebi 2004 [6] Major surgery (20) SO/MCT/OO/FOb SO ASTc, ALTc, CRP, alpha-T,TGc
Barbosa 2010 [7] Sepsis (23) SO/MCT/n-3 TGsd SO/MCT H LOS, ICU LOS, Mortality CRP, EPA, DHA, AA, LTB4, AST, ALT, 
Bilirubin, OI, IL-6, PTT, Lac
Berger 2008 [8] Abdominal aortic 
aneurysm (24)
SO/MCT/n-3 TGsd SO/MCT Mortality, H LOS, ICU LOS EPA, DHA, AA, alpha-T, CRP, TG
Friesecke 2008 [9] Critical medical (165) SO + FOe SO/MCT Mortality, Infection rate, 
ICU LOS, Bleeding events
IL-6f TBU
Heller 2004 [10] Elective colorectal (44) SO + FOe SO ICU LOS AST, ALT, CRP, Bilirubin, PT (Quick), PTT, 
TBU
Morlion 1996 [11] Gastric carcinoma (20) SO + FOe SO AA, EPA, DHA, LTB5, LTB4
Piper 2009
[12] Major abdominal or 
craniomaxillofacial 
surgery (44)
SO/MCT/OO/FOb SO/OO AST, ALT, TG
Roulet 1997 [13] Elective 
oesophagectomy (19)
SO + FOe SO EPA, DHA, AA, BT
Sabater 2011 [14] Acute respiratory distress 
syndrome (44)
SO/MCT/n-3 TGsd SO Mortality LTB4
Wachtler 1997 [15] Elective abdominal 
surgery (40)
SO/MCT/n-3 TGsd SO/MCT Infection rate, H LOS, 
ICU LOS
LTB4, LTB5, LTB ratio, IL-6f
Wang 2008 [16] Severe acute pancreatitis 
(40)
SO + FOe SO Mortality, Infection rate, 
H LOS, ICU LOS
EPA, CRP, OI
Weiss 2002 [17] Gastrointestinal surgery 
(23)
SO + FOe SO Mortality, Infection rate, 
H LOS, ICU LOS
IL-6g
Wichmann 2007 [18] Major intestinal surgery 
(256)
SO/MCT/n-3 TGsd SO Mortality, Infection rate, 
H LOS, ICU LOS
AST, Bilirubin, TG, CRP, LTB5, LTB ratio, 
alpha-T, EPA, PT (Quick), Cr
Elective surgery, non-ICU patients (n = 740)
Badia-Tahull 2010 [19] Major gastrointestinal 
surgery (27)
SO + FOe SO/OO Mortality, H LOS, 
Infection rate
ALT, CRP, TBU, Cr, PlU
Grimm 2006 [20] Radical colorectal cancer 
resection (33)
SO/MCT/OO/FOb SO H LOSc alpha-T, AA, EPA, DHA, LTB4, LTB5, LTB 
ratio
Jiang 2010 [21] Gastrointestinal 
malignancy (203)
SO + FOe SO H LOS, Infection rate, 
Bleeding events
IL-6, CrCl
Klek 2005[22] Major abdominal surgery 
(58)
SO + FOe SO/MCT H LOS, Infection rate ALT, AST, Cr, PlU
Koeller 2003 [23] Major abdominal surgery 
(30)
SO/MCT/n-3 TGsd SO LTB4, LTB5, LTB ratio
Liang 2008 [24] Colorectal cancer (41) SO + FOe SO Mortality, Infection rate, 
H LOS
IL-6
Linseisen 2000 [25] Major abdominal surgery 
(33)
SO/MCT/n-3 TGscd SO alpha-T, AA, EPA, DHA
Makay 2011 [26] Major gastric surgery (26) SO + FOe SO Mortality, Infection rate, 
H LOS
AST, ALT, Cr, PlU; Lac
Mertes 2006 [27] Abdominal surgery (249) SO/MCT/OO/FOb SO Mortality, H LOS AST, ALT, TG, Bilirubin
Senkal 2007 [28] Major abdominal cancer 
(40)
SO/MCT/n-3 TGsd SO/MCT Infection rate AA, EPA, DHA
aAllocation to the ICU subgroup was driven by explicit mention in the published paper of an ICU stay, in the Methods or Results sections of the original article. 
bSMOFlipid 20% (Fresenius Kabi): 1000 ml of emulsion contains: soya-bean oil, refi ned 60.0 g, triglycerides, medium-chain, 60.0 g, olive oil, refi ned 50.0 g, FO, 
rich in n-3-acids 30.0 g. cNot used for meta-analysis as data are from a subgroup of Mertes et al. [27]. dLipoplus 20% (B.Braun): 1000 ml of emulsion contains: 
medium-chain triglycerides: 100.0 g, soybean oil, refi ned: 80.0 g, N-3-acid triglycerides: 20.0 g. eOmegaven 10% fi sh oil emulsion (Fresenius Kabi): 100 ml emulsion 
contains highly refi ned fi sh oil 10.0 g containing  eicosapentaenoic acid (EPA) 1.25 to 2.82 g, docosahexaenoic acid (DHA) 1.44 to 3.09 g, dl-α-tocopherol (as 
antioxidant) 0.015 to 0.0296 g. fData reported by graph only or qualitatively. gNo SD reported. AA, (%) content of arachidonic acid in serum/cellular membranes; 
alpha-T, alpha-tocopherol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BT, bleeding time; Cr, serum creatinine; CrCl, creatinine clearance; CRP, 
C-reactive protein; DHA,(%) docosahexaenoic acid  content in serum/cellular membranes; EPA, (%) eicosapentaenoic acid content in serum/cellular membranes; 
FO, fi sh oil emulsion; Lac, lactate; (H) LOS, (Hospital) length of stay; ICU, intensive care unit;  LTB, leukotriene B; LTB ratio, LTB5: LTB4; (n-3) TGs, (n-3) triglycerides; MCT, 
medium chain triglycerides; OI, oxygenation index; OO, olive oil emulsion; PlU, serum urea; PT, prothrombin time;  PTT, partial thromboplastin time; SO, soybean oil 
emulsion; TBU, transfused blood units.
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